Total returns on $1000
1Y
- 3M
- 6M
- 1Y
- 3Y
- 5Y
Fund/benchmark | Change | |
---|---|---|
Price | RTW Biotech Opportunities Ltd (Ordinary Share) | +10.83% |
NAV | RTW Biotech Opportunities Ltd (Ordinary Share) | +30.87% |
Morningstar's Benchmark | (Russell 2000 Biotech Growth) 50.000% + ( Nasdaq Biotechnology Index) 50.000% | -- |
- Transaction in Own Shares
- Notice of AGM
- Monthly Valuation Update and First Quarter Letter
- Portfolio Company Update: Artios Pharma
- New Investment: Obsidian Therapeutics
- Total Voting Rights
- Annual Financial Report
- Monthly Valuation Update & Factsheet
- Closed Period Notification
- Director/PDMR Shareholding
More ▼
Key statistics
As of last trade RTW Biotech Opportunities Ltd (RTW:LSE) traded at 1.31, -8.39% below its 52-week high of 1.43, set on Jan 31, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Shares outstanding | 385.29m |
---|---|
Market cap | 510.24m USD |
Total assets | 751.31m USD |
Total expense ratio | 1.97% |
High | 1.31 |
Low | 1.31 |
Previous close | 1.31 |
Average volume | 565.57k |
---|---|
YTD Change | -6.60% |
Beta | 0.6203 |
Diluted NAV (est) | 1.95 |
Diluted NAV (last pub) | 1.95 |
Premium/Discount | -32.82% |
Net Gearing | 0.00% |
Data delayed at least 20 minutes, as of Apr 25 2024 14:01 BST.
More ▼